Progenics Stock Drops After Study Reveals Two Deaths in Trial

Progenics Pharmaceuticals Inc., Tarrytown, N.Y., stocks fell nearly 20 percent after a study summary showed two patients died of sepsis in a trial of the company’s experimental prostate cancer treatment. The study abstract appears to show that even at a lower dose of the drug, PSMA-ADC, patients could experience life-threatening levels of toxicity, said Brian Klein, an analyst at New York-based Stifel Nicolaus & Co. Read the full story

More News:

All news »

What are your comments?

Join the discussion today. Login Here.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments